Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Development of a new CRISPR-Cas3-based tool for large genomic deletions

Descrizione del progetto

Una nuova tecnologia per l’editing di ampi segmenti di DNA

La recente introduzione della tecnologia CRISPR-Cas9 ha rivoluzionato l’editing genomico mirato generando piccole inserzioni e delezioni nei siti bersaglio. Il progetto GenDels, finanziato dall’UE, si concentrerà su una tecnologia alternativa basata su CRISPR e sul suo utilizzo dell’enzima Cas3, che combina l’attività elicasica e nucleasica. L’obiettivo è realizzare editing genetico ad alte prestazioni di ampi segmenti di DNA in cellule umane, per applicazioni sanitarie o per decifrare il ruolo delle varianti di DNA non codificanti nelle malattie. Questa tecnologia potrebbe inoltre essere sfruttata per l’editing di cellule batteriche per applicazioni metaboliche e di biologia sintetica.

Obiettivo

The advent of the revolutionary genome editing technique CRISPR-Cas9 has enabled targeted gene mutation, repression, and activation, facilitating impactful biological findings. However, Cas9 as an unbiased DNA deletion tool is limited in its ability to interrogate large regions of DNA of unknown function, because it predominantly generates very small (<20 bp) insertions and deletions at its target site. The capacity to rapidly and efficiently generate large genomic deletions does not currently exist and would be an extremely useful tool for research, allowing for rapid strain engineering of bacterial cells for synthetic biological and metabolic engineering purposes. Additionally, this technology would allow for the interrogation of large segments of non-coding DNA in human cells, much of which has unknown function, but whose variants are often associated with human disease. In this proposal, I aim to develop a Type I-C CRISPR-Cas system employing the Cas3 enzyme (completely distinct from Cas9), which naturally possess coupled nuclease and helicase activity, for high-throughput gene-editing purposes in various prokaryotic, as well as human cells. My preliminary results have shown that this is a credible approach, as I have been able to generate individually, as well as in combination, multiple deletions in bacterial organisms exceeding 60 kb in size. A focal point of the proposal is to adapt this system for use in human cells, which would provide a novel basic research tool with unprecedented capabilities and also could be utilized in human health-related applications. The proposal aims to address this later possibility by utilizing the developed system to treat human cell lines infected with difficult-to-treat pathogenic viruses.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-MSCA-IF-2018

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

EUROPEAN MOLECULAR BIOLOGY LABORATORY
Contributo netto dell'UE
€ 264 669,12
Indirizzo
Meyerhofstrasse 1
69117 Heidelberg
Germania
Regione
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 264 669,12

Partner (1)